Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712060 | 0.87 | MTNR1A (0.40) | MTNR1AMTNR1BPTGS2SCN9ASYK | |
| SCHEMBL1711953 | 0.86 | MTNR1A (0.39) | MTNR1AMTNR1BPTGS2SCN9ASYK | |
| SCHEMBL1711951 | 0.82 | PTGS2 (0.37) | MTNR1AMTNR1BPTGS2 | |
| SCHEMBL2287233 | 0.81 | SCN9A (0.34) | SCN9ASYKSERPINE1PCSK9AAK1 | |
| SCHEMBL3154917 | 0.80 | ACACB (0.38) | — | |
| SCHEMBL3149200 | 0.80 | ACACB (0.38) | — | |
| SCHEMBL1711856 | 0.80 | MTNR1A (0.41) | MTNR1AMTNR1BPTGS2HTR2C | |
| SCHEMBL1722764 | 0.80 | KCNH2 (0.45) | SCN9AAAK1 | |
| SCHEMBL1711943 | 0.80 | MTNR1A (0.42) | MTNR1AMTNR1BPTGS2SCN9AHTR2C | |
| SCHEMBL16333231 | 0.79 | PTGS2 (0.35) | MTNR1AMTNR1BPTGS2AAK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2344495-B1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-8466168-B2 | Tricyclic alkylaminomethyloxazolidinone derivatives | Actellon Pharmaceuticals Ltd. (CH) | 2013-06-18 | — | — | US | disclosed |
| EP-2321307-B1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344495-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2321307-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010015985-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | PYM1, Q6ZSR9, O60361 | MTNR1A 438/4885MTNR1B 431/4885PTGS2 2436/4885 |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | MTNR1A 987/4885MTNR1B 670/4885PTGS2 4023/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | MTNR1A 1089/4885MTNR1B 860/4885PTGS2 3735/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | MTNR1A 1119/4885MTNR1B 897/4885PTGS2 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.